FFAR2/GPR43 Antibody (1000624) [DyLight 550]
Novus Biologicals, part of Bio-Techne | Catalog # FAB10082L
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Monoclonal Mouse IgG2B Clone # 1000624
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 Mouse myeloma cell line transfected with human FFAR2/GPR43
Met1-Glu330
Accession # O15552
Met1-Glu330
Accession # O15552
Specificity
Stains human FFAR2/GPR43 transfectants but not irrelevant transfectants in flow cytometry.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for FFAR2/GPR43 Antibody (1000624) [DyLight 550]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: FFAR2/GPR43
Long Name
Free Fatty Acid Receptor 2
Alternate Names
GPR43
Additional FFAR2/GPR43 Products
Product Documents for FFAR2/GPR43 Antibody (1000624) [DyLight 550]
Product Specific Notices for FFAR2/GPR43 Antibody (1000624) [DyLight 550]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...